Literature DB >> 14607755

V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia.

Veronique M Duke1, Domenica Gandini, Paul D Sherrington, Ke Lin, Bridget Heelan, Peter Amlot, Atul B Mehta, A Victor Hoffbrand, Letizia Foroni.   

Abstract

BACKGROUND AND OBJECTIVES: Given the prognostic relevance that the identification of mutated and germline subgroups of chronic lymphocytic leukemia (CLL) has recently acquired we set out to analyze in depth individual VH gene usage rearrangements in patients with mutated and germline CLL. DESIGN AND METHODS: Using sequence analysis of FR1/JH polymerase chain reaction products, the VH immunoglobulin gene configuration was analyzed in 159 rearranged IgH alleles from 154 CLL patients. Having previously identified a spatial relationship between VH gene usage and JH proximity in patients with acute lymphocytic leukemia (ALL), we performed linear and Poisson regression analysis on patients with germline and mutated CLL against VH rearrangements from normal peripheral blood.
RESULTS: Sequence analysis showed that 102 patients (64%) had mutated sequences (>2% DNA base pair changes) while 57 (36%) had germline sequences. The germline CLL group showed JH proximal overusage similar to that reported in ALL patients, while the mutated CLL group showed a pattern comparable to that of the control group (peripheral blood rearranged VH sequences). The CDR3 region was statistically longer in the patients with germline CLL than in those with mutated CLL. INTERPRETATION AND
CONCLUSIONS: This study highlights differences in the VDJ profile in mutated and germline CLL, consistent with the suggestion that CLL comprises two subgroups. The interpretation of these differences is that the B-cell of CLL, particularly in the germline group, may derive from a pool that has been unable to follow or complete the normal pathway of B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607755

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Authors:  Renee C Tschumper; Susan M Geyer; Megan E Campbell; Neil E Kay; Tait D Shanafelt; Clive S Zent; Grzegorz S Nowakowski; Timothy G Call; Gordon W Dewald; Diane F Jelinek
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

3.  Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.

Authors:  Teresa Sadras; Mickaël Martin; Kohei Kume; Mark E Robinson; Supraja Saravanakumar; Gal Lenz; Zhengshan Chen; Joo Y Song; Tanya Siddiqi; Laura Oksa; Anne Marie Knapp; Jevon Cutler; Kadriye Nehir Cosgun; Lars Klemm; Veronika Ecker; Janet Winchester; Dana Ghergus; Pauline Soulas-Sprauel; Friedemann Kiefer; Nora Heisterkamp; Akhilesh Pandey; Vu Ngo; Lili Wang; Hassan Jumaa; Maike Buchner; Jürgen Ruland; Wing-Chung Chan; Eric Meffre; Thierry Martin; Markus Müschen
Journal:  Mol Cell       Date:  2021-04-19       Impact factor: 17.970

4.  Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia.

Authors:  Ying-Jung Huang; Ming-Chung Kuo; Hung Chang; Po-Nan Wang; Jin-Hou Wu; Yen-Min Huang; Ming-Chun Ma; Tzung-Chih Tang; Ching-Yuan Kuo; Lee-Yung Shih
Journal:  Br J Haematol       Date:  2019-06-23       Impact factor: 6.998

5.  Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.

Authors:  Zijun Y Xu-Monette; Jianyong Li; Yi Xia; Beryl Crossley; Robert D Bremel; Yi Miao; Min Xiao; Thomas Snyder; Ganiraju C Manyam; Xiaohong Tan; Hongwei Zhang; Carlo Visco; Alexandar Tzankov; Karen Dybkaer; Govind Bhagat; Wayne Tam; Hua You; Eric D Hsi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Miguel A Piris; Jane N Winter; Jeffrey T Medeiros; Bing Xu; Yong Li; Ilan Kirsch; Ken H Young
Journal:  J Immunother Cancer       Date:  2019-10-22       Impact factor: 13.751

6.  Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients.

Authors:  Alejandro Medina; Cristina Jiménez; M Eugenia Sarasquete; Marcos González; M Carmen Chillón; Ana Balanzategui; Isabel Prieto-Conde; María García-Álvarez; Noemí Puig; Verónica González-Calle; Miguel Alcoceba; Isabel Cuenca; Santiago Barrio; Fernando Escalante; Norma C Gutiérrez; Mercedes Gironella; Miguel T Hernández; Anna Sureda; Albert Oriol; Joan Bladé; Juan-José Lahuerta; Jesús F San Miguel; María-Victoria Mateos; Joaquín Martínez-López; María-José Calasanz; Ramón García-Sanz
Journal:  Blood Cancer J       Date:  2020-02-06       Impact factor: 11.037

7.  Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China.

Authors:  Zhenshu Xu; Jinyan Zhang; Shunquan Wu; Zhihong Zheng; Zhizhe Chen; Rong Zhan
Journal:  Oncol Lett       Date:  2013-02-05       Impact factor: 2.967

8.  Comprehensive characterization of immunoglobulin gene rearrangements in patients with chronic lymphocytic leukaemia.

Authors:  Céline René; Nathalie Prat; Audrey Thuizat; Mélanie Broctawik; Odile Avinens; Jean-François Eliaou
Journal:  J Cell Mol Med       Date:  2014-04-11       Impact factor: 5.310

9.  [Distinguish immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Chinese patients with chronic lymphocytic leukemia].

Authors:  H Li; T Y Wang; Y Yin; P L Wang; Z Cheng; J P Li; W Li; F Y Zhu; C C Wu; Z M Luo; Y H Chen; H Xiao; S B Deng; Y Q Cao; G S Zhang; L G Qiu; H L Peng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.